Evaluation of the efficacy, tolerability, and safety of 7 days of treatment with GRT6010 or pregabalin in comparison to placebo in subjects with peripheral neuropathic pain.
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2014
At a glance
- Drugs GRT 6010 (Primary) ; Pregabalin
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Grunenthal
- 01 Oct 2014 Status changed from completed to discontinued, as per ClinicalTrials.gov record.
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Mar 2012 Additional trial location (Italy) added as reported by ClinicalTrials.gov.